Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis-Reference-Cited by-同舟云学术

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

Published:2021-10-09 Issue:3 Volume:55 Page:302-310
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Rubin David T.¹^ORCID,Modesto Irene²,Vermeire Séverine³,Danese Silvio⁴^ORCID,Ng Siew C.⁵^ORCID,Kwok Kenneth K.²,Koram Nana²,Jones Thomas V.⁶

Affiliation:

1. University of Chicago Medicine Inflammatory Bowel Disease Center Chicago IL USA

2. Pfizer Inc New York NY USA

3. Department of Gastroenterology University Hospitals Leuven Leuven Belgium

4. Humanitas Clinical and Research Center – IRCCS and Department of Biomedical Sciences Humanitas University Milan Italy

5. Institute of Digestive Disease Department of Medicine and Therapeutics LKS Institute of Health Science The Chinese University of Hong Kong Hong Kong

6. Pfizer Inc Collegeville PA USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16619

Reference20 articles.

1. Ulcerative colitis

2. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

3. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

4. DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

5. Pfizer Inc.Xeljanz®(tofacitinib): highlights of prescribing information.http://labeling.pfizer.com/ShowLabeling.aspx?id=959

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis;Dermatologica Sinica;2024-09-04

2. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

3. Personalised therapy in inflammatory bowel disease;Gastroenterología y Hepatología (English Edition);2024-08

4. Shared Immune Associations Between COVID-19 and Inflammatory Bowel Disease: A Cross-Sectional Observational Study in Shanghai, China;Journal of Inflammation Research;2024-03

5. Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis;Journal of Clinical Medicine;2024-01-29